# Chinese Pain Pill Blocked My COX's Source: https://www.youtube.com/watch?v=G7ME5mwpfuo Recap page: https://rapidrecap.app/video/G7ME5mwpfuo Generated: 2025-11-23T23:33:49.567+00:00 --- ## Quick Overview The Chinese ibuprofen extended-release capsules, containing 0.3g Ibuprofen, caused the presenter's immediate relief from elbow inflammation because the extended-release mechanism broke down too quickly in his stomach, leading to immediate absorption rather than the intended slow release, which he later found was similar to how some NSAIDs cause cardiovascular issues by completely blocking protective COX-1 enzymes. **Key Points:** - The presenter purchased Chinese extended-release Ibuprofen capsules (300mg) in Delaware County from an Asian grocery store because this formulation is unavailable by prescription in the US. - The extended-release mechanism failed because the internal spherical beads dissolved rapidly upon reaching the stomach, causing immediate, non-sustained release of the drug. - The immediate effect was significant pain relief in the presenter's inflamed elbow within three hours, suggesting the drug was absorbed quickly. - The presenter notes that blocking COX-1 enzymes (which protect the stomach and kidneys and keep blood sticky) can lead to adverse effects like ulcers and increased risk of cardiovascular disease. - The NSAID chart shows Ibuprofen has a low COX-1/COX-2 IC50 ratio (0.5), indicating it is less selective for COX-2 (anti-inflammatory) compared to drugs like Rofecoxib (267). - The rapid breakdown of the extended-release mechanism meant the body was suddenly exposed to a high concentration of the drug, potentially increasing risk compared to a true sustained release. ![Screenshot at 00:04: The presenter, Grant Harting, holds up a box of Chinese Ibuprofen extended-release capsules, noting his excitement to test a Cox blocker that is unavailable in the United States.](https://ss.rapidrecap.app/screens/G7ME5mwpfuo/00-00-04.png) **Context:** The video features a licensed pharmacist, Grant Harting, examining a box of Chinese-marketed Ibuprofen 300mg extended-release capsules, which are not sold in the US. He performs a simple test by opening a capsule and observing the internal beads on a paper plate to demonstrate the failure of the extended-release mechanism, relating this quick breakdown to the known pharmacological risks associated with non-selective NSAID action on COX enzymes. ## Detailed Analysis The presenter, Grant Harting, who is a licensed pharmacist in four states, discusses an over-the-counter Chinese medication he purchased: Ibuprofen 300mg extended-release capsules (Fenbid). He bought them at an Asian grocery store in Delaware County because this extended-release formulation is not available in the US without a prescription. Harting explains that standard NSAIDs work by blocking COX enzymes, specifically COX-1 and COX-2. COX-1 protects the stomach and kidneys and keeps blood from getting too sticky, while COX-2 is primarily associated with inflammation. Blocking COX-1 can lead to side effects like stomach ulcers and increased cardiovascular risk. He demonstrates that the extended-release mechanism of the Chinese capsules failed; when he opened one, the 300mg dose was contained in many small, crushable beads that dissolved immediately on a paper plate, meaning the drug was released instantly rather than slowly over 12 hours. He took one capsule for his inflamed elbow and reported significant relief after three hours, suggesting the rapid absorption worked for his acute pain, though he points out that this immediate release is contrary to the intended function and still carries the risk associated with high initial drug levels. He references a chart showing Ibuprofen has a low COX-1/COX-2 IC50 ratio (0.5), meaning it is less selective for COX-2 (anti-inflammatory) than some other NSAIDs, increasing the risk of COX-1 related side effects if the drug concentration is too high. ### Product Introduction and Acquisition - Presenter holds up Chinese Ibuprofen 300mg extended-release capsules (Fenbid) bought in Delaware County because they are not available by prescription in the US - The presenter notes he injured his elbow and is trying this product for inflammation. ### Extended-Release Mechanism Test - Presenter crushes a capsule, revealing numerous white, spherical beads inside, which immediately dissolve on a paper plate, demonstrating a failure of the intended slow-release mechanism - He notes the beads are crushable and dissolve easily, indicating immediate absorption upon ingestion. ### Pharmacology of NSAIDs - Explains that NSAIDs block COX enzymes (COX-1 and COX-2) which convert arachidonic acid into prostaglandins - COX-1 protects the stomach/kidneys and keeps blood sticky; COX-2 causes inflammation - Blocking COX-1 can lead to ulcers and cardiovascular risk. ### Selectivity Chart Analysis - Displays a chart comparing NSAIDs based on their COX-1/COX-2 IC50 ratio, where lower numbers indicate greater COX-1 selectivity (less anti-inflammatory effect) and higher numbers indicate greater COX-2 selectivity (more anti-inflammatory effect with lower GI risk) - Ibuprofen (0.5) and Naproxen (0.7) are shown to be more COX-1 selective, while Celecoxib (30) and Rofecoxib (267) are more COX-2 selective. ### Experimental Results and Conclusion - After 3 hours, the presenter felt inflammation relief in his elbow, confirming the drug worked, but likely due to the immediate release rather than the intended extended release - He concludes that while the product worked for his pain, the failure of the extended-release mechanism is an important concept for understanding drug delivery and potential side effects. ![Screenshot at 00:05: The presenter holds up the Chinese extended-release Ibuprofen box while explaining his motivation for trying the drug to treat elbow inflammation.](https://ss.rapidrecap.app/screens/G7ME5mwpfuo/00-00-05.png) ![Screenshot at 00:47: Google Lens translation overlay showing the English text 'Ibuprofen extended-release capsules' on the Chinese packaging.](https://ss.rapidrecap.app/screens/G7ME5mwpfuo/00-00-47.png) ![Screenshot at 01:52: A chart comparing the COX-1/COX-2 IC50 ratios for various NSAIDs, illustrating Ibuprofen's lower selectivity for COX-2 compared to drugs like Celecoxib and Rofecoxib.](https://ss.rapidrecap.app/screens/G7ME5mwpfuo/00-01-52.png) ![Screenshot at 04:21: The presenter pops open the blister pack, revealing the orange and white capsules, and expresses surprise at the design.](https://ss.rapidrecap.app/screens/G7ME5mwpfuo/00-04-21.png) ![Screenshot at 05:10: Close-up shot showing the tiny white spherical beads that make up the extended-release component of the capsule, spread out on a paper plate.](https://ss.rapidrecap.app/screens/G7ME5mwpfuo/00-05-10.png)